KEY POINTS
- This international patterns-of-care survey was conducted on behalf of the ESTRO Head and Neck Focus Group, using 34 questions covering pretreatment evaluation, radiotherapy, systemic therapy and supportive care for older patients with head and neck squamous cell carcinoma (HNSCC). Between September and December 2025, 85 radiation oncologists participated, with 63 completing the final questionnaire section. Among respondents reporting geographic origin, 41.3% practiced outside Europe, while 76.6% of those reporting institution type worked in academic centers. Participation was voluntary, and the overall response rate could not be determined.
- Chronological age remained a major factor in treatment decisions despite limited use of structured geriatric assessment. An age threshold of 70 years was used by 47.0% of respondents, compared with 65 years in 19.3% and 75 years in 18.1%; only 15.7% used no specific age threshold. Performance status was assessed by 92.9%, but formal comorbidity scoring was used by only 32.1% and geriatric screening, predominantly G8, by 25.0%. Activities of Daily Living and nutritional risk scores were used by just 13.1% and 2.4%, respectively. Non-European respondents applied significantly lower age thresholds than European respondents (p<0.001).
- Definitive target-volume selection showed greater consistency than postoperative treatment planning. Bilateral elective nodal irradiation was reported by 85.9% of respondents in the definitive setting, compared with 65.7% after surgery. In postoperative treatment, 20.0% irradiated only the involved neck side and 11.4% restricted elective coverage to involved nodal levels. Overall, 35.2% reported adapting target volumes according to age, comorbidity or tumor stage. Pretreatment PET/CT was routinely used by 61.9%, while HPV status was routinely assessed in 73.8% of institutions treating older patients with oropharyngeal cancer. Importantly, 80.3% did not routinely de-escalate treatment for p16-positive disease.
- Approximately half of respondents reported withholding concurrent chemotherapy beyond a predefined age threshold. Conversely, 52.2% in the definitive setting and 50.7% postoperatively would administer chemotherapy when indicated and medically feasible regardless of age. Among those applying age restrictions, thresholds ranged from 65 to 80 years, with a median of 70 years. Weekly cisplatin was the most frequently reported regimen, used by 59.7% for definitive and 62.7% for postoperative chemoradiotherapy. Renal eligibility criteria varied: 56.9% considered GFR or creatinine clearance <60 mL/min a contraindication, compared with 27.7% using 50 mL/min and 12.3% using 40 mL/min. Pre-existing hearing impairment was considered a contraindication by 77.9%.
- Hypofractionation was the most frequently reported alternative when concurrent chemotherapy was unsuitable. Overall, 52.1% considered alternative dose or fractionation strategies, including hypofractionation above 2.5 Gy per fraction (40.8%), reduced total dose (18.3%) and split-course treatment (14.1%). Supportive care practices also varied considerably: nutritional counseling was offered by 95.5%, but routine speech and swallowing therapy by only 42.4%, physical therapy by 30.3%, and prehabilitation by 21.9%. 48.5% routinely recommended prophylactic gastrostomy, while 60.9% did not routinely offer prehabilitation programs.
- Two clinical scenarios exposed major differences in treatment intensification and de-escalation decisions. For a 76-year-old patient with cT3N0 hypopharyngeal cancer, 85.7% recommended bilateral elective nodal irradiation, but treatment recommendations were almost evenly divided between concurrent chemoradiotherapy (49.2%) and radiotherapy alone (50.8%). For a 74-year-old patient with resected p16-positive oropharyngeal cancer and extranodal extension, 63.5% would omit concurrent chemotherapy, despite extranodal extension being a conventional indication for postoperative chemoradiotherapy. Only 39.7% recommended bilateral cervical irradiation, while 50.8% favored ipsilateral treatment and 9.5% treated the involved nodal level only.
- The survey identifies variation in physician-reported practice rather than proving differences in treatment quality or outcomes. Respondents were predominantly academic specialists, participation was voluntary, and the number of physicians receiving the survey invitation was unknown. The questionnaire did not collect patient-level treatment decisions, locoregional control, survival or toxicity outcomes, and its exploratory geographic comparisons were not corrected for multiple testing. Furthermore, the survey preceded several important publications and approvals involving immunotherapy and proton therapy, limiting its ability to reflect the most recent management strategies.
CLINICAL TAKEAWAY
The ESTRO survey highlights substantial international variation in the management of older patients with HNSCC, particularly regarding chemotherapy eligibility, postoperative target volumes, hypofractionation and supportive care. Chronological age continues to influence treatment decisions despite relatively limited adoption of structured geriatric screening. These findings support more systematic assessment of fitness, comorbidity and patient priorities, but do not establish which treatment modifications improve clinical outcomes.